Prospects of elafibranor in treating alcohol-associated liver diseases DOI

Wanzhen Cui,

Huadan Xue, Daimin Wei

et al.

World Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 31(2)

Published: Dec. 18, 2024

Alcohol-related liver disease (ALD), which is induced by excessive alcohol consumption, a leading cause of liver-related morbidity and mortality. ALD patients exhibit spectrum injuries, including hepatic steatosis, inflammation, fibrosis, similar to symptoms nonalcohol-associated diseases such as primary biliary cholangitis, metabolic dysfunction-associated steatotic disease, nonalcoholic steatohepatitis. Elafibranor has been approved for the treatment cholangitis shown improve in both animal models vitro cell However, efficacy elafibranor treating remains unclear. In this article, we comment on recent publication Koizumi et al that evaluated effects fibrosis gut barrier function an mouse model. Their findings indicate potential treatment, but further experimental investigations clinical trials are warranted.

Language: Английский

Early Liver Transplantation in Severe Alcohol-associated Hepatitis DOI Creative Commons
Jordi Colmenero, Elisa Pose, Hugo López‐Pelayo

et al.

Revista Española de Enfermedades Digestivas, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Early liver transplantation for severe alcohol-associated hepatitis represents a transformative therapeutic approach that can significantly improve survival and achieves standard after LT compared to other indications. evaluation an adequate selection of candidates, including organic psychosocial criteria, are essential. Multidisciplinary management, the addiction team treatment alcohol use disorder, decreases risk relapse is associated with improved outcomes.

Language: Английский

Citations

0
Prospects of elafibranor in treating alcohol-associated liver diseases DOI

Wanzhen Cui,

Huadan Xue, Daimin Wei

et al.

World Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 31(2)

Published: Dec. 18, 2024

Alcohol-related liver disease (ALD), which is induced by excessive alcohol consumption, a leading cause of liver-related morbidity and mortality. ALD patients exhibit spectrum injuries, including hepatic steatosis, inflammation, fibrosis, similar to symptoms nonalcohol-associated diseases such as primary biliary cholangitis, metabolic dysfunction-associated steatotic disease, nonalcoholic steatohepatitis. Elafibranor has been approved for the treatment cholangitis shown improve in both animal models vitro cell However, efficacy elafibranor treating remains unclear. In this article, we comment on recent publication Koizumi et al that evaluated effects fibrosis gut barrier function an mouse model. Their findings indicate potential treatment, but further experimental investigations clinical trials are warranted.

Language: Английский

Citations

0